Led · Series D · Aug 2026

Abcuro develops immunotherapies intended to benefit people with debilitating and progressive rare autoimmune diseases by selectively targeting and depleting highly cytotoxic T cells. Its lead program, ulviprubart, is a monoclonal antibody that targets killer cell lectin like receptor G1 (KLRG1) and is currently being evaluated for the treatment of Inclusion Body Myositis (IBM). The company plans to use proceeds from the Series D to support a new potentially registrational clinical study of ulviprubart in patients with less severe IBM. Abcuro is led by CEO Alex Martin and is based in Newton, MA. Financially, it has just completed a $66M Series D financing led by New Leaf Venture Partners with participation from a broad syndicate of life sciences and strategic investors.

Participated · Equity · Jan 2026

BrightInsight delivers a cloud-based platform that enables life-science companies to rapidly develop, launch, and scale compliant digital health solutions such as patient companion apps, digital-first patient support programs, and Software as a Medical Device tools. Its technology captures real-world data and helps pharmaceutical partners differentiate flagship therapies while improving medication adherence and persistence. The company supports initiatives like the Patient App created in collaboration with Sanofi and Regeneron and aims to expand these offerings across a broad range of diseases and therapies globally. BrightInsight’s roadmap includes further AI-enabled features to enhance medication-persistence analytics. Led by CEO Kal Patel and headquartered in San Jose, CA, the firm works with biopharma customers worldwide to deliver measurable clinical and business value through digital interventions.

Led · Series E · May 2024

Truveris operates a proprietary technology platform that replaces traditional PBM contracting and renewal models by creating a transparent, dynamic competitive marketplace. The platform drives savings on pharmacy pricing and improved contract terms while providing ongoing analysis of 100% of claims to ensure contract compliance and program optimization. Truveris serves self-insured employers nationwide with comparative procurement, deep insights, and member engagement solutions. The company plans to continue evolving its platform to further transform and reduce pharmacy spend for employers and plan members. The recent financing is intended to support Truveris’ next stage of corporate development and operational growth. Truveris emphasizes its independent, data-led approach to delivering PBM pricing transparency. Truveris offers a cloud-based analytics platform that aggregates data across the pharmacy ecosystem to deliver cost savings, patient access, and affordability solutions for employers, unions, government entities, manufacturers, retail pharmacies, and consumers. Its TruBid® solution enables clients to understand and shop PBM contracts, perform continuous bill review, and has driven an average cost reduction of 11% for customers. The company works with more than 350 customers, including nearly 30 labor unions, and supports over 25 pharmaceutical brands on patient access strategies. Truveris also operates the OneRx consumer app that helps insured and uninsured users research drug and pharmacy pricing. The platform was credited with saving the State of New Jersey $1.6 billion on prescription drug benefits. The company says the new funding will accelerate growth and expand availability of its platform across the prescription benefits market, a $450 billion industry. Truveris provides prescription-payments auditing software that uses an index of drug costs to check billed prices against pharmacy charges. The company launched its first product in 2009 and later introduced TrueBid, a marketplace for buyers and sellers of pharmaceutical payment plans. TrueBid is described as an “eBay for prescription benefits” and is aimed at improving bidding workflows and transparency for pharmacy benefits managers. Truveris is rolling out a reporting service for benefits managers that combines data warehousing and customized reports, planned for launch in the fourth quarter. The company serves about 200 customers representing 30 million members and its software processes 300 million claims annually, covering roughly 10% of U.S. drug spend. The recent financing was raised to support the rollout of these new products. Truveris builds cloud-based software (notably TruBid and TruGuard) to help payers, brokers and employers negotiate with PBMs and verify prescription-claims billing in real time. Its TruBid product automates RFPs and reverse auctions to PBMs, helping payers drive up to 12% savings annually, while TruGuard catches billing errors prior to payment. The company reports serving 11 million participants and has reviewed more than 100 million claims through its platform. Truveris says its solutions enforce standard contract terms, ensure pricing definitions and support CMS guidelines for Medicare-eligible pharmacy benefits. Founded in 2009 and based in New York City, Truveris plans to use new capital to expand its development and operations teams and to reach government entities, health insurers, self-insured corporations and unions across the U.S. The company has recruited industry veterans with prior executive roles at major health-plan and PBM organizations to support growth and product deployment. Truveris operates a scalable, automated claims-analysis engine that audits prescription claims for cost accuracy, member cost share, eligibility, fraud, SOX and RDS compliance, and other health analytics. Its service allows payers to verify and pay Pharmacy Benefit Managers only for correctly priced and adjudicated claims prior to payment. Since being founded in 2009, Truveris has reviewed more than 100 million prescription claims and attracted 30 customers. The company will use new funding to expand product development and field operations targeting government entities, health insurers, self-insured corporations, and unions across the United States. Management highlights a large market opportunity: every two weeks invoices for over $12 billion in prescription claims are paid without review, and roughly 5% are inaccurately billed. The team includes talent from University Health Plans, Hewitt, Fairview Pharmacy Services, and Bioscrip.

Led · Series B · Apr 2024

Qlaris Bio is a clinical-stage biotechnology company focused on developing novel therapies for serious ophthalmic diseases; it was founded in August 2019 and is based in Dedham, Mass. Its lead program, QLS-111, is a first-in-class therapeutic designed to lower intraocular pressure by targeting episcleral venous pressure via ATP-sensitive potassium channel modulation. The science originated in the lab of Dr. Michael Fautsch at Mayo Clinic, and preliminary data suggest QLS-111 is well tolerated without significant hyperemia or safety concerns. Qlaris is currently conducting two U.S. Phase II trials (Osprey and Apteryx) in open-angle glaucoma and ocular hypertension and anticipates initiating the Nightingale Phase II trial in normal-tension glaucoma by the end of 2024. The company intends to use recent financing proceeds to support continued clinical development and execution of its clinical strategy for QLS-111. Investors tied to the company include Canaan, New Leaf Venture Partners, Correlation Ventures, Mayo Clinic Ventures, and funds managed by abrdn Inc.

Led · Series C · Mar 2024

Flosonics Medical is a Canadian medical device company (founded 2015, Sudbury, Ontario) that develops FloPatch, a wireless wearable Doppler ultrasound designed to deliver rapid, repeatable hemodynamic assessments at the bedside. FloPatch aims to help clinicians assess fluid responsiveness and streamline critical decisions in sepsis and other acute-care settings, reducing fluid-related complications and improving patient outcomes. The company positions the device as a faster, more accessible alternative to traditional Doppler ultrasound machines in emergency and intensive care environments. Flosonics says the funding will accelerate market adoption and enable broader hospital deployment across North America and beyond. The announcement highlights the company’s focus on non-invasive, data-driven solutions and ongoing clinical research to support its technology. Financially, Flosonics secured venture debt to support scaling operations and commercialization efforts. Flosonics Medical develops FloPatch, a first-in-class wearable Doppler ultrasound designed for hemodynamic assessments. The device is intended to improve management of critically ill patients and support monitoring both inside and outside the hospital. The company emphasizes continued evidence generation to validate clinical use. Flosonics plans to expand indications for use and accelerate commercial growth and market adoption. The firm is a Canadian medical device company based in Sudbury, Ontario, founded in 2015. Recent financing will be used to support innovation, expansion, and broader deployment of its wearable AI-assisted sensor technology. Flosonics Medical is a venture-backed medical device company developing the FloPatch, a low-cost, wearable Doppler ultrasound sensor that adheres to a patient’s neck and sends hands-free blood flow data wirelessly via low-energy Bluetooth. The company says FloPatch enables on-demand, non-invasive Doppler measurement of blood flow to support management of critically ill patients across emergency, OR, ward, and ICU settings. Its first product, the FloPatch FP 120, has received regulatory clearances from the FDA and Health Canada. Founded in 2015 and headquartered in Sudbury, Ontario, Flosonics employs over 20 people focused on R&D. Financing proceeds will be used for a commercial launch in North America and for new product development as the technology transitions to clinical use.